The partial hold comes after Nurix told the agency of its plan to “transition to an improved manufacturing process,” the drugmaker said in a Nov. 1 news release.
The study is testing Nurix’s drug NX-2127 and involves 160 adult participants with relapsed or refractory B-cell malignancies, according to clinicaltrials.gov. Patients already receiving treatment will continue their regimens, but new enrollment is currently paused with the clinical hold.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
